ASCIA COVID-19 update
9 November 2020:
In Australia and New Zealand the response to the COVID-19 pandemic has been world leading, with minimal community transmission. However, outbreaks have occurred, and work continues on prevention and treatment of COVID-19, including new vaccines. The ASCIA COVID-19 Working Party will meet in early 2021 to discuss the COVID-19 vaccines and possible allergic reactions. In the meantime we will be monitoring the experiences and responses from authorities in other countries.
COVID-19 Clinical Evidence TaskForce Living Guidelines
The Australian government's National COVID-19 Clinical Evidence TaskForce Living Guidelines are available at https://covid19evidence.net.au/ and these are updated weekly with the latest research. As a result of these guidelines, ASCIA documents for health professionals about COVID-19 treatments have been “retired”. The ASCIA COVID-19 webpage www.allergy.org.au/patients/covid-19 still includes links to ASCIA information about COVID-19 for patients, consumers and carers.
ASCIA Representation on RACP COVID-19 Expert Reference Group
ASCIA now has a representative (Dr Theresa Cole) on the Royal Australasian College of Physicians (RACP) COVID-19 Expert Reference Group (ERG), which did not previously include any ASCIA members. This ERG meets fortnightly on Tuesday via Zoom, provides expert advice to the RACP on COVID-19 policy, advocacy issues and organisational matters, and regularly reviews and provides feedback on Government COVID-19 resources.
The RACP has mentioned ASCIA anaphylaxis e-training in a letter they recently sent to the Hon Greg Hunt, Minster for Health regarding the planning for the distribution and roll out of COVID-19 vaccinations. The letter states All vaccine providers should also be trained in rapid emergency treatment of severe allergic reactions (anaphylaxis)1. Reference 1: The Australasian Society of Clinical Immunology and Allergy (ASCIA) provides anaphylaxis e-training.